Thanks, everyone. morning, good and Prahlad,
came the a as year our Prahlad and quarter note strong mentioned, results we on in guidance. As finished above solidly our expectations fourth
all fully While in not to appear our be demand right they amongst customers, direction. does the have and yet that move pharma at things stabilized may it trends have starting normalized least
and performance with back was our markets leveraged quarterly performance diligent aggressive more to we $XXX high a adjusted financial balance those We share of initiatives, operating our and control. on be quarter the both sheet margin worth This strong continue able phase, appear our As our are to levels in evident another cash XX.X% our in remain to shares. we our were remain in to in of of repurchase million fully as position our activity recovery buy generation. which
which we we years. X last generated As In continue deliver financial total well to company growth, organic above be above the as high revenues in performance to have organic fourth of revenue growth performed differentiated X% of the our the achieved to quarter. the and in resulting end the was was fairly the look broad-based Sciences expectations both each outperformance million, The we Diagnostics of positioned slightly expectations. ahead XXXX, adjusted over $XXX our Life quarter, our our segments
strength above dollar was continued life This health software our in Our and than reagents persisting in and to FX instrumentation businesses offset a over expectations points saw greater-than-anticipated our which basis expectations, by headwinds. last challenges reproductive the science months. FX our headwind, business nearly several we XXX the performed stronger worse was was due and X% business.
no incremental had acquisitions. contribution again also from We
billion year, M&A. organic modest growth was of generated FX $X.XX of headwinds For X% revenue, the comprised we total and impact no adjusted which from full
in generated we expectations the with growth P&L, our adjusted increased the XX.X% to margins investments quarter organic which offset some relates line our were operating upside. it as in As
For our of expansion points power of and our XX which adjusted for approximately demonstrates year-over-year margin given our the only operating represented XX.X%, were year, the X% growth organic full basis business margins the year.
and the net was other year line, in expense full to adjusted interest $XX million, we expectations with brought interest our $XX below and adjusted had other expense of net and million. line the Looking which
quarter in $XXX.X This Our continue which diluted EPS fourth from adjusted was was of the above adjusted $X.XX resulted in in adjusted tax high in headwinds. share benefits initiatives. see year we the of a and of XX.X%.
With rate million FX rate despite guidance pressure full recent average of this to the XX.X% in planning tax unanticipated end as above the quarter, an tax $X.XX, approximately our count our $X.XX quarter midpoint from of resulted $X.XX the
of was adjusted year-over-year. guidance above $X.XX X% the our of the which year, beginning the our EPS For and midpoint was represented initial full year $X.X, at the growth
million, year We our P&L. net again to of equating full free perspective, in the beyond to from free our cash strong a brought This a had Moving of flow the XX% quarter. $XXX adjusted flow generating quarter $XXX cash million income. cash conversion
off, potential about I as area am on additional excited paying enter the we in Our and this for XXXX. improvements clearly focus cash is
fourth ratio in As additional This year now also $XXX growth repurchase million presentation in the full and our quarter X% up quarter far XXXX deploying in over with adjusted full Asia, with and net on we of remains repurchases Life was leverage grew the China Americas activity Board digits our another in in digits. this worth active the brought X single some on EBITDA now Despite comprised million authorization Relations our on billion digits our repurchasing slide remained in remaining quarterly growth the single for just strong so in high website.
The trends, we million in activities $X last Between Geographically, debt X% have growth digits and we which X% of are as new Europe of and $XXX a our organic year million segment Investor in quarter some grew to approximately the provide in mid-single balance received will capital, $XXX fourth we by our the this revenue quarter buyback activity, Sciences nearly fourth business grew our we January, year in included our and shares. years finish low this sheet the mid-single in Diagnostics. October. from X.Xx.
I the to commentary combined. $XXX
growth organic declining genomics. single declined single-digit and single growth For double-digit China mid-single-digit also China Life the and decline our X% growth for immunodiagnostics by and low declines and in saw The in Life health, Asia our low whole low single Sciences both and in offset digits the achieved single low growth reagents grew X% Diagnostics in in experienced Americas growth applied mid-teens we X% with for a with year, in growth digit, double-digit full low year.
Within digits, the grew quarter, high Sciences. We growth Diagnostics with Europe in single-digit we consumables reproductive in instrumentation. with digits,
Sciences in adjusted Life year, X% our was performance businesses and Sciences, a the with a in reported and region.
From generated segment full on the across China basis. life mid-single-digit organically in both the science low our digits business of the similar in immunodiagnostics $XXX For declined including reagent Diagnostics up total and revenue organic both single this growth Life perspective, million quarter,
and into year. low first first in positive base digits customers the of the fourth XXXX.
Sales full biotech Sciences From quarter the this full biotech The For quarter quarter down growth year, pharma growth the was government perspective, since the our Life from in customer declined for into the digits customer the quarter a the of business low single digits organically. pharma single the single the low from in rose the academic low declined was the and in mid-single-digit mid-single in for rose and in in year. sales customers digits single digits quarter
instrument down total Sciences about XXXX in year. and high Life in of Life double represented full digits Sciences the digits revenue low for quarter single XX% down revenue was and the Our
technology an and for Our about which approximately included in services XX% and and Life year-over-year. digits Sciences point pharma the digits reagent lower low licensing basis the represented specialty and in revenue grew revenue from of single declined mid-single year, in headwind the revenue quarter XXXX XXX licensing
of year. Finally, low quarter up in Sciences for represented remaining the business, in revenue more and the was the in our teens XXXX, grew than the software Signal which XX% Life XX%
basis portfolio renewals. an X% software a Signals adjusted This net value.
In had metrics, business on basis. annual growth of SaaS rate and reported in segment, year which growth XX% recent our its Diagnostics million in As its was another we on some of Investor highlighted quarter, the XXX% in double-digit in annualized total up to our with X% first generated resulted specific we its $XXX recurring over Day, our XXXX the at revenue it industry revenue in pertains of in organic retention which
organically. business was full X% For our up Diagnostics the year,
our the digits was in Our XX% quarter total XXXX, grew in the up revenue single in digits represented year. full and immunodiagnostics business organically mid-single for the diagnostic and high of
Our quarter XXXX, revenue health high Diagnostics reproductive which the total in XX% mid-single organically and of was single for in about digits the represented business, in grew digits up year. full the
applied quarter, by organically total significant was pharma/biotech our occurred the double genomics impacted better low during was represented anticipated roughly year. and of the revenue the we full in Finally, than business, levels low the remaining in continues the during digits build-out the which in XXXX, This spend slightly the of which be grew XX% lower single had business digits that for pandemic. to down capacity Diagnostics and
during third encouraging for to quarter, growth it excluding see to quarter However, time return XXXX. first the a COVID, was the the since of
XXXX, starting reminder, this folded over within we segment quarter to Consequently, immunodiagnostics the which be on will our our applied business specifically being Sciences in report will its moving with Diagnostics into last genomics a remainder of As performance business unit. Life the quarterly most our in a as be segment.
to Now our for outlook looking XXXX. ahead
customers few signs may trends it months that to does be stabilized show Life starting from the last least and discussed, As our Sciences have demand over of at eventual appear improvement. some
historically more of normal to towards throughout continue path this this expect We levels demand year.
to our and will more modest back we of being, to that in X we to this expecting year. our more long-range last but the the X% improvement our normalized company plan.
Consequently, time compared looking things growth, this year an which X% are total current total outlook growth we the to year expected growth assume we our for levels currently of not organic regulatory we've in backdrop, of be the our organic the in X% that of start to X% the expectations.
With company upside throughout would the to growth X% end be things each levels first uncertainties range significant the improve, is X% organic to If for current here experienced improvement not year. are represent to for quarter are growth expected as in this growth the markets year any years with balanced including However, in this it political meaningfully exist, given for assuming more
approximate to for This an assumed the FX year equates With the the approximate assuming as in be of our recent to to of reported quarter. for here XXXX expected an strength the year and from in the our December, for FX end revenue assumed to This headwind X% assumed X.X% in range headwind $X.XX headwind to year. overall dollar, rates the X.X% the a to exchange currently headwind X.X% is the first be full contribution no acquisitions. EPS given revenue results growth in
range We all to billion to total XXXX $X.X this of in expect a be our billion result to in $X.XX overall. revenue
continue are assuming overall it overall.
We XX.X% expansion XX.X% of range margin operating XX I resulting pertains As internal and cash anticipate, investments, levels we is adjusted our Despite spending, in in Prahlad of restructuring our year, margins still performance XXXX. in planning this as in display investments which, fantastic XXXX, being points this as planned potential to our investment in had on more strategic step-up will of are mentioned, power year. expected operating the generation margin step basis after X up to restricted XX of to our the years we be this to to
lower up low-cost following have cuts.
Consequently, level year million after given cash in will other rate had fourth expense of our and $XXX significantly lower we we a interest run the approximately last this million year, the expect net be on quarter. off consistent interest balances and million over our cash from income overall $XX here the $XX we to recent our shown However, last returns paying debt rate lower expense but year, in with net this year quarterly
year, global also pressure to upward some to As reform had our this actively modest recent Day November, are which we this in tax from working to to Investor the We tax at year be our through net approximately have in in offset of up on previewed tax we rate our rate we expect XXXX. expect had the our planning XX%, XX.X% impact result full initiatives. currently adjusted we
share year full which Lastly, year. anticipating we are continues approximately modest diluted the average $XXX assumes activity of count repurchase throughout a million,
higher to $X, all this year expect full We earnings full expected approximately of year rate $X.XX quarter year. a in our to in XXXX XX% start to to in range be occur the of tax a result initial earnings to adjusted of the with first share our per given
continuing Given in expect an million additional generation million expect continued to market, robust focus our strong in flow more proceeds we this as financial for of would which step-up not approximately expansion return line levels are and up $XXX does more free now front to spending, expect $XX its a differentiated cash anticipated we operator, a growth.
Overall, another initiatives, this progress profound our result approximate that, of include once cash on to well the Despite improving to to to even top we investment like finish of levels solid receive see on starting from back us a with should externally call to our having XXXX, open is us significant the which the position company growth in to impact the margin AES patients' of more and future. new had divestiture. to innovations planned opportunities move Overall, Revvity which to lives.
With normal and transformed to questions. in show of year year, we deliver of we in trends strong potential while XXXX expect we
